Category: Clinical research
- Zengguang Chen, Jing Huang, Jing Wang, Yiyang Zhan & Qianwei Sun
Admission cMyC measured by POCT was independently associated with 30-day MACE in patients with AMI. cMyC may serve as a rapid adjunctive biomarker for early risk stratification, although its incremental predictive value requires further validation.
- Pedro Lopez-Ayala, Jasper Boeddinghaus, Luca Koechlin, et al
CMyC adds significant incremental value to hs-cTn values in the early diagnosis of NSTEMI, improving diagnostic discrimination and enabling more patients to be safely and immediately ruled out for NSTEMI. The single blood draw dual-biomarker strategy is particularly attractive in busy ED settings due to its simplicity and quick time-to-decision.
- Michael F. Paus, Magnus N. Lyngbakken, Arnljot Tveit, et al
In the general population, circulating cMyC concentrations are associated with cardiovascular risk factors, reflect left ventricular remodelling, including focal myocardial fibrosis, and systolic and diastolic dysfunction independently of traditional risk factors.
- E. Riveland, A. Ushakova, T. Valborgland, et al
Changes in levels of the novel biomarker cMyC were significantly associated with hs-cTnI serum levels in patients
with symptomatic chronic HFrEF during a structured 12-week exercise training programme. This may indicate that cMyC
has a role as a future marker of subclinical myocardial damage.
- E Riveland, A Ushakova, T Valborgland, et al
Changes in levels of the novel biomarker cMyC were significantly associated with hs-cTnI plasma levels in patients with
symptomatic chronic HFrEF during a structured 12-week exercise training program. Being more sensitive may indicate a role as a future
marker of subclinical myocardial damage.
- Adriana Chetran, Minerva Codruta Bădescu, Ionela Lăcrămioara Serban, et al
The study brings new evidence supporting the role of MyBP-C as a comprehensive biomarker in AHF. While NT-proBNP remains the gold standard biomarker in AHF, MyBPC has been shown to have an impressive diagnostic performance with high sensitivity and specificity, providing complementary information. MyBP-C may serve as a valuable adjunctive tool in enhancing diagnostic accuracy and guiding clinical decisions in AHF.
In addition, MyBP-C has a promising role as a prognostic biomarker in AHF, being able to complement existing markers, and thus achieve better risk stratification and the prediction of short-term outcomes.
- Bashir Alaour, Thomas E Kaier, Rasmus Bo Hasselbalch, et al
We have previously shown that significant circadian oscillations exist for cardiac troponin T (cTnT) but not for cardiac troponin I (cTnI).
Cardiac myosin-binding protein C (cMyC) is a novel protein biomarker of myocardial injury with a promising role in the diagnosis and risk stratification of acute myocardial injury.
In this study, we examine and compare the diurnal variation of cMyC with cTnT/I.
- Michael Mallouppas , Robin Chung , Arjun K. Ghosh , Alison Macklin , Derek M. Yellon , and J. Malcolm Walker
cTnT and cMyC significantly increased during anthracycline chemotherapy.
- Vincent L. Aengevaeren , Roland R. J. van Kimmenade , Jordi Ordóñez‐Llanos , et al.
Because postexercise cTn elevations can be challenging to interpret in the clinical setting because of concentrations exceeding the URL in the absence of signs of myocardial ischemia, a parallel assessment of cMyC might aid in discerning whether cTn elevations are physiological or pathological in endurance athletes.
- Bashir Alaour, Torbjørn Omland, Janniche Torsvik, et al
cMyC exhibits acceptable RCV and low II suggesting that it could be suitable for disease monitoring, risk stratification and prognostication if measured serially. Analytical quality specifications based on biological variation are similar to those for cardiac troponin and should be achievable at clinically relevant concentrations.
- Thomas Nestelberger, Jasper Boeddinghaus, Pedro Lopez-Ayala, et al
cMyC concentrations, which may quantify cardiomyocyte injury even more accurately than hs-cTnT or hs-cTnI levels, were lower in T2MI vs T1MI and provided modest diagnostic accuracy, comparable with that provided by hs-cTnT and hs-cTnI.
- Nikola Kozhuharov, Desiree Wussler, Thomas Kaier, et al.
cMyC (Cardiac Myosin-Binding Protein C) may aid physicians in the rapid triage of patients with suspected Acute Heart Failure (AHF).
- Thomas E. Kaier, Carsten Stengaard, Jack Marjot, et al.
cMyC is superior to hs-cTnT to rule-out chest pain patients with final AMI diagnose with blood-samples done at time of ambulance pickup.
- Xiang-Jian Chen, Wei Zhang, Zhi-Ping Bian, et al.
cMyBP-C is the first cardiac-specific protein to be regarded as a promising diagnostic biomarker for acute myocardial injury since Troponin (cTn).
Circulating cMyBP-C is a promising novel biomarker for evaluating cardiac surgical trauma in patients undergoing a cardiac operation.
- T E Kaier, R Twerenbold, B Alaour, et al.
A newly developed cMyC AMI rule-in/rule-out pathway identifies a greater proportion of patients suitable for safe rule-out as compared with the ESC 0/1h-algorithm using hs-cTnI and thus reduces the number of patients in a diagnostic grey zone.
- Atul Anand, Calvin Chin, Anoop S V Shah, et al.
Serum cMyC concentration is associated with myocardial hypertrophy, fibrosis and an increased risk of mortality in aortic stenosis.
- Thomas E. Kaier, Raphael Twerenbold, Christian Puelacher, et al.
Using cMyC to triage on first blood draw results in fewer patients in grey zone compared with hs-cTnT and hs-cTnI.
- Thomas E Kaier, Atul Anand, Anoop S V Shah, et al.
In these early presenters, cMyC is relatively higher than cTnI on presentation and then cTnI catches up.